UBS analyst Eliana Merle downgraded CureVac (NASDAQ: CVAC) from Buy to Neutral with a price target of $5.50 (from $12.00).The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE